Sickle Cell Anemia News featured an article about the Food and Drug Administration’s (FDA) recent approval of Immucor’s PreciseType HEA test to screen blood donors for the sickle cell trait (SCT). The test quickly and accurately predicts blood compatibility between donors and patients to prevent alloimmunization (immune response to foreign antigens after exposure to genetically different cells or tissues) in patients.
“Our previous screening methods required manual testing and interpretation of the results and had high false positive rates,” said Connie Westhoff, SBB, PhD, Executive Director of Immunohematology, Genomics and Rare Blood at NYBC. “We are now able to identify SCT in our donors utilizing the same PreciseType HEA test we are already running on many of our donors without running additional tests.”
Click here to view the entire article.